Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Carcinoma, Non-Small-Cell Lung 42Breast Neoplasms 28Parkinson Disease 4, Autosomal Dominant Lewy Body 23Neoplasms 22Multiple Myeloma 18Leukemia, Myeloid, Acute 14Neoplasm Metastasis 11Carcinoma, Renal Cell 10Leukemia 10Melanoma 10Ovarian Neoplasms 10Recurrence 10Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Adenocarcinoma 8Carcinoma, Hepatocellular 8Colorectal Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Lung Neoplasms 8Myelodysplastic Syndromes 8Prostatic Neoplasms 8Stomach Neoplasms 8Lymphoma, Follicular 7Bronchiolitis Obliterans Syndrome 6Carcinoma 6Lymphoma 6Lymphoma, Non-Hodgkin 6Small Cell Lung Carcinoma 6Urinary Bladder Neoplasms 6Cholangiocarcinoma 5

Interventions

Emapalumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Has announcements × Lymphohistiocytosis, Hemophagocytic × Clear all
NCT01818492 2023-02-21

Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis

Swedish Orphan Biovitrum

Phase 2/3 Completed
45 enrolled 20 charts 1 FDA
Myeloid

Lymphohistiocytosis, Hemophagocytic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡